Armen Shanafelt - 07 Jun 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Reporting relationship: Director
Issuer ticker: SYRE
Reported as of: 07 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2022, 21:22:33 UTC
Prior SEC filing: 13 Dec 2021
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ James Kastenmayer, by power of attorney

Key filing fact

Armen Shanafelt filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 09 Jun 2022.

Key facts

This page summarizes Armen Shanafelt's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2022, 21:22.

Change

Previous filing in this sequence was filed on 13 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGLE transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +43,000
Change %
Price: $0.000000
Shares after: 43,000
Date: 07 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,000
Exercise price: $0.7300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.